ASX Announcement
10 January 2025

Advanced Health Intelligence Granted Significant US Patent
"ASSESSING DISEASE RISKS FROM USER CAPTURED IMAGES"

Highlights

- **Represents significant IP value increase for AHI.**
- **Provides AHI exclusivity to Assessing Multi-Category Disease Risk from User Captured Images according to the claimed systems and methods.**
- **AHI has developed unique image processing techniques.**
- **Competitive Advantage: Patent protection safeguards AHI's innovative approach.**

Advanced Health Intelligence Ltd **(ASX:AHI) ("Advanced Health Intelligence", "AHI", or "the Company")** is pleased to announce a significant milestone, having received a US patent for "Assessing Disease Risks from User-Captured Images." (U.S. Patent No. 12,191,040).

The issuance of this patent represents a major milestone for AHI. It adds to the Company's current intellectual property (IP) portfolio and strengthens its position as a leader in the innovative field of health risk assessment. The patent ensures strong IP protection and underscores the uniqueness and novelty of AHI's technology, being the ability to provide users with an assessment of the user's risk of disease, including in some examples, metabolic diseases, cardiovascular diseases, stroke, and other conditions directly related to obesity. By safeguarding its proprietary methods, AHI effectively prevents unauthorised third parties from replicating or misusing its techniques to analyse user-captured images for multi-category health risk identification.

This protection allows AHI to maintain a competitive edge. Also, it positions AHI as a pioneer at the intersection of digital health and artificial intelligence (AI), contributing to advancing personalised healthcare solutions.

AHI's latest Patent: *"Assessing Disease Risks from User-Captured Images."*

AHI has been granted a patent that significantly enhances its IP portfolio. This patent has far-reaching consequences for competitive applications, particularly given the rapidly growing digitisation of the MedTech-health care sector worldwide.

As AI continues to be rapidly adopted in the healthcare sector, user-captured images are poised to become a critical data source for training and enhancing AI models, driving the expansion of algorithmic analytical capabilities. Organisations intending to use such methods as detailed in the granted patent must obtain permission from AHI to ensure compliance with its protected IP, or they would be in breach of the patent. In the event AHI identifies any party breaching its newly granted patent protection, the Company will take steps to enforce its rights. In appropriate cases, AHI may enter into an arrangement with the breaching party, enabling them to continue their ability to provide users with a disease risk assessment using the systems and methods protected by AHI's patent under agreed-upon commercial terms.

The patent's scope is comprehensive, encompassing scenarios in which an individual uses digital images to capture information that is then processed, including body shape, features, biometrics, or shape indicators. The information extracted identifies health risks that can be provided to health care professionals to facilitate health advice, including diagnosis, early intervention and the escalation of care. AHI's patent applies if a patient employs a digital camera to capture body or feature images that are subsequently used in health risk identification as claimed in the granted patent. This patent strengthens AHI as a key stakeholder in the digital transformation that the global health care ecosystem is undergoing, providing AHI with a competitive edge and protection to the substantial segment of the market where organisations are attempting to improve patient care and early intervention through digital identification of health risks.

AHI's patent has the potential to significantly impact organisations that use digital device images to assess risk. AHI has spent significant time, capital, and resources developing these unique processes and pursuing the goal of making health care accessible, efficient, and patient-centric. As the healthcare landscape continues to evolve, AHI's innovation and commitment to excellence will play a vital role in shaping the digitisation of medical care, improving outcomes, and enhancing patients' lives worldwide.

AHI continues successfully expanding its patent coverage for its technology suite, further strengthening its position in the early intervention, chronic disease identification and remote digital care space.
With the increasing adoption of remote digital health assessment and care globally, expanding AHI's patent portfolio is a strong focus to cement its position as a market leader in health and medical innovation.

The recently awarded patent is a significant addition to AHI's IP portfolio, demonstrating a commitment to protecting its proprietary technology. As AHI identifies unique functionalities proprietary to the Company, it will continue to strengthen its position, providing deeper coverage and more protection from potential competitors.

As industry MedTech leaders such as Roche, Medtronic and Johnson and Johnson, alongside consumer tech giants including Apple, Google, Microsoft, and Samsung, continue to invest in personal diagnostics and Software as Medical Devices (SaMD), AHI aims to demonstrate how its unique solutions can augment their existing offerings. Our platform is designed to complement their technologies by delivering comprehensive health assessments that go beyond single-sensor approaches. AHI believes its patented technology offers significant value to these companies, enhancing their methods in feeding their AI-powered health risk assessment capabilities and capturing phenotypical data that is currently beyond the reach of their existing methods.

AHI's Global Vision: Addressing a Growing Market
AHI's proprietary risk assessment application which is now protected by the US issued patent, addresses a critical gap in healthcare by offering a technology-driven approach to identify risks related to obesity and metabolic diseases. With over 1.9 billion adults globally classified as overweight or obese, the market for advanced screening tools is vast.

While other apps may offer some diagnostic capabilities based off self-captured images, with the grant of its new patent, AHI has the exclusive right to provides users' risk assessments for various diseases using their proven methodologies, including assessing chronic diseases such as metabolic diseases and other conditions directly related to obesity (including non-communicable diseases), helping to address a global health crisis that impacts billions of individuals.

By leveraging this new patent, AHI is uniquely positioned to serve healthcare providers, insurers, and individuals seeking early intervention strategies to combat obesity-related diseases.

Obesity is a modifiable risk factor that is directly associated with some of the most prevalent and costly non-communicable diseases (NCDs). Obesity places immense stress on the cardiovascular system, increasing the risk of hypertension, coronary heart disease, heart failure, and stroke. Excess fat contributes to plaque buildup in arteries, heightening the likelihood of heart attacks and strokes. These conditions represent a significant portion of global mortality.

Obesity is also a risk factor for:

- various cancers, including breast (post-menopausal), colorectal, pancreatic, and kidney cancers;
- respiratory disorders like obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS);
- musculoskeletal digestive disorders;
- mental and reproductive health issues (including anxiety and infertility); and
- dementia and Alzheimer's disease.

This patent represents a transformative step forward in global health innovation, enabling AHI to partner with healthcare organisations to reduce the global burden of obesity and its associated conditions. By providing personalised, data-driven insights, AHI empowers individuals to take proactive measures to improve their health outcomes and quality of life.

ASX Announcement
10 January 2025

Strategic Expansion of Intellectual Property Portfolio

The grant of our new US patent marks a significant milestone, as the US is widely regarded as a primary and educated IP system. This achievement lends substantial credibility to our IP, facilitating expansion into additional global jurisdictions.

With this US patent in place, has already commenced lodgements of the new IP to:

- Expand patent coverage into key jurisdictions across Asia, MENA, the US, and Europe.
- Develop partnerships and use cases in telehealth, population screening, insurance, and large corporate employers.
- Enhance global distribution channels with our unique and proprietary IP.

Protecting our IP is crucial to maintaining our market position and delivering shareholder value. Adding the 'Assessing Disease Risks from User-Captured Images' patent to our portfolio further strengthens AHI's position in the market.

Vlado Bosanac, Head of Strategy at AHI, said:

"AHI intends to solidify its leadership in health risk assessment with groundbreaking technology that it will continue to patent. The granting of AHI's patent for "Assessing Disease Risks from User-Captured Images" cements its position as an innovative pioneer in health risk assessment technology. This patent showcases AHI's capability to harness digital device images to identify and assess potential health risks, highlighting the unique value of its proprietary solutions.

"AHI will Continue to Strengthen our Competitive Advantage: This patent significantly fortifies AHI's competitive position, creating a substantial barrier to entry for competitors seeking to develop similar technologies. Organisations interested in implementing digital health risk assessment solutions based on user-captured images must explore alternative approaches or engage in licensing agreements with AHI, ensuring compliance with our protected IP.

"Strategic Partnerships and Industry Impact: AHI anticipates that industry leaders will recognise the strategic value of incorporating AHI's patented technology into their health care offerings. By integrating our innovations, these companies can enhance their data capture capabilities, expand their AI-driven health risk assessment models, and gain a competitive advantage in the rapidly evolving digital health landscape.

"AHI is Fostering Innovation and Collaboration: As AI continues to transform the health care sector, AHI believes user-captured images are a vital data source for advancing AI models and expanding algorithmic analytical capabilities. AHI remains committed to driving innovation and collaboration in the sector by exploring licensing opportunities with selected organisations. This strategy ensures the integrity of AHI's IP while opening up new revenue streams and driving progress in personalised health care solutions."

AHI boasts an extensive and growing global patent portfolio, with granted patents in key markets, including Australia, the United States, Japan, South Korea, Singapore, New Zealand, China, Canada, and Europe. AHI continues to pioneer, ensuring that it remains at the forefront of the demand for digital health innovation.

The Chairman and CEO of Advanced Health Intelligence Ltd have approved this announcement.

For more information, please visit: www.ahi.tech.

Laura Wilson
Chief Marketing Officer
Advanced Health Intelligence Ltd
E: media@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

About Advanced Health Intelligence Ltd

AHI offers cutting-edge, smartphone-based health risk identification solutions that enable individuals to run their own comprehensive health assessments and risk stratification.

Utilising smartphone sensor technology, individuals can efficiently conduct a single scan or a series of scans to identify established risk markers for various health conditions. The resulting data can then be shared with health care providers, insurers, employers, and government agencies, facilitating timely triage and appropriate care pathway allocation.

AHI's scientific research capability is dedicated to the development of advanced data capture techniques, optimising data input signal quality and continuous enhancement and validation of AHI's solutions through rigorous scientific processes. AHI has assembled a team of experts in machine learning, artificial intelligence, biomathematical modelling and systems biology, computer vision, clinical expertise, and medically trained data scientists to develop and deploy these cutting-edge risk assessment tools.

Over the past decade, AHI has been at the forefront of health-tech innovation, pioneering the use of smartphones in digital-first health care. Our journey began with the groundbreaking development of the world's first on-device body dimensioning capability.

Since then, we have continued to evolve and adapt our solutions to meet the dynamic needs of health systems players dedicated to delivering high-quality patient care and early detection of escalating health conditions. AHI's patented technology has enabled us to push the boundaries of early detection through digital health care, offering a suite of modular solutions that are transforming the industry and offering earlier intervention opportunities.

Our comprehensive solutions encompass:

- Anthropometric and body composition analysis to identify obesity-related comorbidities, including diabetes risk stratification.
- Predictive modelling of blood biomarkers (including HbA1C, HDL-C, LDL-C), and 10-year cardiovascular risk estimation.
- Facial photoplethysmography to assess vital signs non-invasively and provide risk stratification for cardiovascular disease.
- Device-derived dermatological image analysis for identifying over 588 skin conditions across 134 categories, including melanoma detection.
- Atrial Fibrillation technology enables the detection of Atrial Fibrillation using a mobile device. This allows for early identification and monitoring of this common heart condition through a simple, non-invasive, and user-friendly smartphone-based solution.

AHI has developed digital biomarker-driven triage solutions that use only a smartphone or web browser. These solutions enable the identification of health risks across populations and can inform direction of individuals to appropriate care pathways for proactive health management. The technology provides cost-effective health risk assessment access to billions of smartphone users worldwide, empowering these individuals to take charge of their health journey and improving health outcomes globally.